Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32574262&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Interferon-alpha2b Treatment for COVID-19 #MMPMID32574262
Zhou Q; Chen V; Shannon CP; Wei XS; Xiang X; Wang X; Wang ZH; Tebbutt SJ; Kollmann TR; Fish EN
Front Immunol 2020[]; 11 (ä): 1061 PMID32574262show ga
The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-alpha2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-alpha2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-alpha2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-alpha2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-alpha2b should be further investigated as a therapy in COVID-19 cases.
free
free
free
Front+Immunol 2020 ; 11 (ä): 1061
